Major advances are being made in identifying the structure and behaviour of regulatory cascades that control the activity of cation-Cl − cotransporters and certain Na + , K + and Cl − channels. These transporters play key roles in regulating arterial blood pressure as they are not only responsible for NaCl reabsorption in the thick ascending limb and distal tubule of the kidney, but are also involved in regulating smooth muscle Ca 2+ levels. It is now apparent that defects in these transporters, and particularly in the regulatory cascades, cause some monogenetic forms of hypertension and may contribute to essential hypertension and problems with K + homoeostasis. Two families of kinases are prominent in these processes: the Ste-20-related kinases [OSR1 (oxidative stress-responsive kinase 1) and SPAK (Ste20/SPS1-related proline/alanine-rich kinase)] and the WNKs [with no lysine kinases]. These kinases affect the behaviour of their targets through both phosphorylation and by acting as scaffolding proteins, bringing together regulatory complexes. This review analyses how these kinases affect transport by activating or inhibiting individual transporters at the cell surface, or by changing the surface density of transporters by altering the rate of insertion or removal of transporters from the cell surface, and perhaps through controlling the rate of transporter degradation. This new knowledge should not only help us target antihypertensive therapy more appropriately, but could also provide the basis for developing new therapeutic approaches to essential hypertension.
INTRODUCTION
The last few years have been an exciting time for clinicians and physiologists interested the regulation of membrane transporters involved in volume regulation. We are beginning to unravel and identify a cascade of kinases that control the activity of members of the CCC (cation-Cl − cotransporter) family, whose members are involved in such diverse processes as the regulation of cell volume, Cl − and K + content and, through their activity in the kidney, arterial BP (blood pressure) [1, 2] . The importance of phosphorylation in regulating the activity of these transporters has long been appreciated, but, despite much effort, the identities of the regulatory kinases and phosphatases have eluded us. The work described in this review identifies key regulatory kinases and, importantly, suggests origins, and perhaps therapeutic strategies, for some types of essential hypertension. These advances have arisen from the synergy of two very different experimental approaches: molecular genetics and transport biophysics. Two related families of molecules stand out in these processes, the Ste-20-related kinases, including SPAK (Ste20/SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive kinase 1), and the WNKs (with no lysine kinases) [3] [4] [5] [6] .
We have witnessed major breakthroughs in the identification of genes that may contribute towards the development of essential hypertension [7] [8] [9] [10] . Analysis shows that many tens of genes are involved in regulating BP and defects in any one could give rise to pathology. However, it may prove possible to divide sufferers (or potential sufferers) into a manageable number of subgroups with defects in particular aspects of BP control, and for whom a particular therapy or intervention is appropriate. Whereas genome-wide linkage analysis has produced disappointing results, the analysis of single gene polymorphisms, whose major feature is either raised or lowered BP, has led to the identification of several genes that, if defective, could give rise to hypertension. Interestingly, all of the genes identified so far code for proteins that are involved in regulating NaCl reabsorption in the kidney. Given the importance of CCCs in NaCl reabsorption in the kidney and the fact that they are the targets for drugs used to treat hypertension, this review will focus on the regulation of kidney CCC activity.
NaCl-reabsorbing modules
NaCl reabsorption in each nephron segment is brought about by a group of transporters that can be thought of as a NaCl-reabsorbing module. At the coarsest level, these are very similar throughout the nephron: basolateral Na + pumps removing Na + from the cell and providing power for the entire process, an apical Na + entry route to allow Na + uptake from the urine, and other transporters to balance charge movement. At a finer level, the apical Na + entry route is specific to a particular nephron region, and the nature of that route will put different demands on charge-balancing mechanisms. Thus Na + pumps, packed into the basolateral membranes, transport Na + vigorously from cell to interstitium, reducing cell [Na + ] and producing a gradient for Na + entry across the apical membrane. A distinguishing feature of each segment is the nature of the Na + entry route. In the proximal tubule, there are many different Na + transporters, but in the TAL (thick ascending limb), DCT (distal convoluted tubule) and CD (collecting duct) single transporters dominate, namely NKCC2 (Na + -K + -2Cl − cotransporter 2), NCC (Na + -Cl − cotransporter) and ENAC (epithelial Na + channel) respectively [1, 11] . Entry of Na + across the apical membrane must be closely matched to loss through the Na + pump, and charge transfer across each membrane must be balanced (flux of cations must equal that of anions), usually by fluxes through K + and Cl − channels. There is cross-talk between transporters in the same membrane and between the apical and basolateral membranes to ensure this, and to maintain cell composition and volume in the face of enormous trans-epithelial fluxes (see [12] for an elegant introduction to modelling and understanding of these systems). The nature of the cross-talk, the way in which transporters behave both individually and as communities, is the subject of much current research. A topic of particular interest is how the density of active transporters in a membrane is regulated by changing the activity of individual molecules and by inserting or removing transporters from the surface. How the cell can discern what is going on and how it computes appropriate responses under different physiological conditions is a major conundrum.
One suggested mechanism for the genesis of essential hypertension is that NaCl is too avidly reabsorbed in the latter part of the nephron where there is less scope for compensation in succeeding regions. As tubuloglomerular feedback regulates Na + delivery to the distal nephron within narrow limits, the most likely segments to be involved are the TAL (includes the signalrelaying macula densa), DCT and CDs. The cause of overactive NaCl reabsorption could lie in any part of the NaCl-reabsorbing mechanism in these regions, including (i) the Na + entry route together with its regulatory molecules; (ii) molecules that regulate Na + pump activity; (iii) basolateral Cl − transporters and their regulators; and (iv) transporters that allow apical and basolateral recycling of K + and their regulators. Clearly, there is plenty of scope to explain why tens of genes may be involved.
CCCs
HUGO (Human Genome Organization) recognizes more than 40 families of solute carriers (SLC) in the human genome. NKCC2 and NCC are CCCs belonging to the SLC12 family [13] . There are nine family members, seven with clearly defined transport properties, three of these transporting Na + , Cl − and sometimes K + (SLC12A1-SLC12A3) and four transporting only K + and Cl
There are two NKCCs that transport Na + and K + along with Cl − , both of which are inhibited by low doses of loop diuretics (bumetanide and furosemide). NKCC1 (SLC12A2) is expressed ubiquitously, whereas NKCC2 (SLC12A1) is only found in the apical membrane of the TAL. NCC (SLC12A3) which transports only Na + with Cl − is restricted to the apical membrane of the DCT and is inhibited by low doses of thiazide diuretics. Thus two members of the SLC12 family are exclusively found in the kidney and are the targets for two commonly prescribed classes of drugs, the loop and thiazide diuretics, that are so frequently used to treat volume overload or hypertension.
The cotransporters are large hydrophobic proteins with 12 transmembrane domains. Large N-and Ctermini are cytoplasmic, act as binding sites for kinases, phosphatases and other regulatory molecules, and can be phosphorylated. They may be involved in proteinprotein interactions with other SLC12 members. Activity of the cotransporters is regulated not only by the concentration of substrate ions, but also by phosphorylation of multiple sites, and is heavily influenced by cell volume and [Cl − ], as well as by oxygen levels, hormones and growth factors. The cotransporters move equal numbers of anions and cations across the cell membrane, so, although large numbers of ions move, the process is electroneutral; no current is generated and transport rate is not affected by changes in membrane potential [1] .
Na

+ pumps
Packed into the basolateral membranes at high concentrations, Na + pumps power the entire system. Each pump consists of an α and β subunit [14, 15] . In total, there are four different α and three different β subunits (products of different genes), many of which are expressed in the kidney, providing a rich variety of pumps, although no kidney-specific combinations have been identified. Complexity is increased further by the association of the pumps with small regulatory molecules from the FXYD family [16] . One of these (FYXD2) is also known as the γ subunit of the pump and is expressed in the kidney [16] . Other FXYD proteins are also expressed in specific nephron regions, so certain aspects of pump regulation may occur exclusively in the kidney. Thus kidney-specific defects in Na + pump regulation could have an impact on BP regulation. It is worth noting that inhibition of α-2 Na + pump subunits by an endogenous ouabain-like compound may contribute to the increased vascular tone in salt-dependent essential hypertension [17] .
TRANSPORT IN THE TAL
NKCC2 (Table 1) provides the route for Na + entry in the TAL (Figure 1 ). Na + is accompanied by K + and Cl − ions and, as both the Na + pump and NKCC2 bring K + into the cell, this can accumulate and hinder uptake by the cotransporter. In addition, the avid removal of K + from the urine can reduce its concentration to a level where this also inhibits uptake by the cotransporter. These problems are solved by allowing K + to leave the cell across the apical membrane through ROMK (renal outer medullary K + ; Table 1 ) channels, which are ATPsensitive and inwardly rectifying [18] [19] [20] [21] . Thus K + is recycled across the apical membrane, maintaining internal and external [K + ] at levels that permit efficient operation of NKCC2. Although the majority of K + traverses the apical membrane through the ROMK channel, some may enter through Ca 2+ -activated maxi-K + channels which may become more active in response to stretch induced by high urine flow rates [21] . K + is also recycled across the basolateral membrane (perhaps involving Kir7.1 [21] The TAL is an important site for the reabsorption of Ca 2+ and Mg 2+ from the urine [24, 25] . The recycling of K + across the apical membrane results in the urine having a potential that is positive with respect to blood. This potential favours the reabsorption of cations through the paracellular pathway, the permeability of which is regulated by claudins in the tight junctions [26] 
NKCCs
Three splice variants of NKCC2, which have subtle differences in the structure of cation-binding sites within the second transmembrane domain, are expressed in the TAL. These have different Na + and Cl − affinities to match the composition of the urine which changes as it flows up from the inner medulla to the cortex [28] [29] [30] [31] . The medullary TAL expresses isoform F (low-Na + and Cl − affinities), whereas the cortical TAL expresses isoform A (higher Na + and Cl − affinities), and the macula densa expresses isoform B (highest Cl − affinity). In the mouse, C-terminal truncated versions of these three variants also exist, so that there are six variants of NKCC2 in total [32] . There is evidence that these truncated forms bind to the full-length forms to alter their transport characteristics.
Key to understanding the regulation of Na + uptake by the TAL is knowledge of the way in which the activity of NKCC2 is controlled. Unfortunately, relatively little work has been carried out directly on NKCC2 and thus many of its properties have been inferred by analogy from studies of the closely related CCC family member NKCC1 [1, 2, 33, 34] . This transporter, which is found universally in cells (NKCC1 is sometimes referred to as the house-keeping isoform of the NKCCs), is far easier to work on, and several useful functional experimental models exist that allow close examination
Table 1 Transport proteins and their regulators
The names of the key transporters and their regulators appear in the literature in a bewildering range of forms. The first column gives the common name, followed by its abbreviation used in this review. Alternative names and abbreviations, including those which occur in UniProtKB/Swiss-Prot (http://ca.expassy.org) are also provided, along with gene names (common alternatives in parentheses) and human chromosomal location. 
Figure 1 Transport in the TAL
The red arrow indicates that activation of CASR by Ca 2+ or Mg 2+ inhibits ROMK channels.
of its behaviour and regulation in physiological contexts. NKCC1 activity is strongly affected by phosphorylation of several of its threonine and serine (but not tyrosine) residues [1, 35, 36] . Recent attention has focussed on three threonine residues in close proximity within the N-terminus of the transporter, residues that are highly conserved throughout the CCC family. Phosphorylation of these results in activation of transport [37, 38] . Phosphorylation of one (Thr 189 in shark cotransporter sNKCC1) is absolutely necessary for transport activation, whereas phosphorylation of the others (Thr 184 and Thr 202 ) moderates the effect. Studies have shown that phosphorylation of equivalent threonine residues in NKCC2 occurs in response to cell shrinkage and vasopressin [39, 40] , suggesting that this transporter is regulated in a similar fashion. However, in this case, it requires substitution of all three threonine residues to abolish transport, whereas substitution of any one of the residues has little effect and substitution of two reduces transport [40] . Dephosphorylation of these sites in NKCC1 is probably by PrP1 (protein phosphatase 1), which binds to a nearby motif in the N-terminus [41] . The absence of this site from NKCC2 was thought to explain why NKCC2 expressed in Xenopus oocytes has a higher basal activity than NKCC1; the transporter could be more phosphorylated. However, splicing the Nterminus of NKCC1, with its phosphatase-binding site, on to NKCC2 had no effect on transport [40] , dispelling this notion.
For many years the identity of the kinase or kinases responsible for phosphorylating the cotransporter was unknown, although there were several plausible candidates, including JNK (c-Jun N-terminal kinase) [42] and SGK1 (serum-and glucocorticoid-regulated kinase 1) [43] . Analysis of the conditions under which the transporter is phosphorylated or dephosphorylated suggests several kinases and phosphatases may be involved [44, 45] . Experiments initially using yeast twohybrid screens to identify NKCC-binding partners strongly suggest that SPAK and OSR1 (Table 1) may phosphorylate some of the N-terminal sites in NKCC1 and, importantly, NKCC2 [4, [46] [47] [48] [49] .
Ste20-related kinases: SPAK and OSR1
SPAK and OSR1 (Table 1) are serine/threonine kinases belonging to the Ste-20 kinase superfamily, which plays important roles in cell signalling, including cell-cycle control, growth and response to stress [3] . It is now clear that this family is intimately involved in cell volume and [Cl − ] regulation, a role it has played throughout evolution [3] . SPAK and OSR1 are closely related members of a germinal centre kinase subgroup (GCK-VI). OSR1, the product of a more ancestral gene (OXSR1; Table 1 ), is expressed in most tissues, whereas SPAK, which probably evolved after the amphibia, is found mainly in neurons and transporting epithelia, with its expression closely paralleling that of NKCC1 [4] . It is found in the cytoplasm and in association with the spectrin cytoskeleton [50] .
Although there was strong evidence for the binding of SPAK and OSR1 to the N-terminus of NKCC1 and NKCC2 and a binding motif was identified [46] , there was little to suggest that the kinases could phosphorylate the transporters, so it was believed that SPAK and OSR1 acted as scaffolding molecules, bringing together components of a stress-response complex on the surface of the cotransporters [47] . In subsequent experiments, overexpression of a kinase-dead SPAK inhibited both transport by, and phosphorylation of the key regulatory threonine residues on, NKCC1 expressed in HEK (human embryonic kidney) cells [48] . This suggested that SPAK might phosphorylate the regulatory threonine residues on the transporter, although, curiously, deletion of the SPAK-binding domain did not affect activation of the transporter [47] . The ability of SPAK to phosphorylate the cotransporter was later confirmed in studies using NKCC1 expressed in HEK cells, MDCK (Madin-Darby canine kidney) cells and Xenopus oocytes [49, 51, 52] . However, the threonine residues phosphorylated by SPAK were identified as Thr 175 , Thr 179 and Thr 184 (sNKCC1) [49] , but importantly not Thr 189 , which had been identified previously as playing a key role in transport regulation. One possibility is that phosphorylation by SPAK permits phosphorylation of the cotransporter by another, as yet unidentified, kinase. Kinase inhibitors (for instance staurosporine) that inhibit transport by NKCC1 were found to inhibit NKCC1 phosphorylation by SPAK and SPAK autophosphorylation [52] .
Expression studies [51] also show that NKCC1 can be phosphorylated and activated by OSR1 as long as this was co-expressed with another kinase, WNK4 (see below), which had been earlier identified as a potential binding partner in yeast two-hybrid screens [47] . There is now clear evidence that WNK4, and the related WNK1, phosphorylate and activate both OSR1 and SPAK [51, 53, 54 ] (see Figure 3) . In Xenopus oocytes NKCC1 can be maximally activated under isotonic conditions if co-expressed with both SPAK and WNK4, whereas under hypertonic conditions NKCC1 is maximally active without addition of either of these molecules, the transporter presumably being activated by the oocytes own second messenger systems [53] . It appears that a kinase cascade that regulates NKCC activity in response to osmotic stress and cell [Cl − ] has finally been identified. Some, but not all, elements in this pathway have been shown to operate for NKCC2 as well as NKCC1 [40] . However, it should not be forgotten that the cotransporter is also activated by phosphorylation of other threonine and serine residues in the N-and C-termini of the transporter [35, 36] . For instance, activation of the cotransporter by hypoxia is not associated with any increase in threonine phosphorylation [55] .
Bartter's disease
Bartter's disease encompasses a group of rare autosomalrecessive disorders characterized by salt-wasting, polyuria and hypotension with hypokalaemia and metabolic alkalosis [1, 2, 56] . The condition results from an inability of the TAL to reabsorb Na + due to defects in any one of the components that constitute the NaCl-reabsorbing mechanism in this nephron segment, and it mimics the effects of intoxication with loop diuretics. Currently there are five subtypes, the first four resulting from inactivating mutations to NKCC2 (Type I), ROMK (Type II), CLCKB (Type III) and Barttin (Type IV), all of which prevent transepithelial Na + movement from urine to blood (Figure 1 ). Interestingly, a form of Bartter's disease (Type V) results from gain-of-function mutations in the extracellular Ca 2+ sensor (CASR). This causes inactivation of the ROMK channel preventing K + recycling and thus inhibits transepithelial Na + movement [21] . Note that an almost identical phenotype results from a variety of defects in any of the vital components of the Na + -reabsorbing module in the TAL, including routes for Na + entry, K + recycling and Cl − exit as well as in feedback controllers.
TRANSPORT IN THE DCT
The human DCT consists of two segments (DCT1 and DCT2) that differ in the extent to which Na + entry across the apical membrane occurs through the NCC [11] (Figure 2 ). NCC transports both Na + and Cl − ions in an electroneutral fashion. It is coded by gene SLC12A3 and, in mammals, is only found in the apical membranes of the DCT [1, 11, 57] , although the bladder of the winter flounder provides a useful functional model for studying the properties of the transporter [58, 59] . In DCT1, virtually all Na + entry is by NCC, whereas in DCT2 some
Figure 2 Transport in the DCT
Upper cell, transport in DCT1 where Na + uptake is exclusively by NCC. Lower cell, transport in DCT2. Na + uptake occurs through NCC and ENAC operating in parallel.
also occurs in parallel by ENAC [11] (Figure 2 ). Cl − that enters the cells by NCC leaves across the basolateral border by the kidney-specific Cl − channel CLCKB (with its subunit Barttin). ROMK channels found in the apical membrane probably maintain a negative membrane potential to assist the reabsorption of Mg 2+ and Ca 2+ . In DCT1, Na + reabsorption is electroneutral, whereas in DCT2 it is increasingly electrogenic requiring increased apical K + secretion or paracellular Cl − reabsorption.
The DCT is a highly dynamic structure. If subjected to extra Na + load, for instance when a patient is treated long-term with loop diuretics, it grows and increases its capacity to reabsorb Na + , compensating for deficient Na + transport in other segments. On the other hand, if NCC is inhibited by long-term thiazide treatment, DCT cells die, and there is reduced capacity not only for Na + reabsorption, but for other ions too (for instance Mg 2+ ) [60] .
Unlike other CCC family members, relatively little is known about the regulation of NCC activity; for instance, about the consequences of phosphorylation of particular residues on transport rate [59] , although it is known that SPAK and OSR1 phosphorylate threonine residues equivalent to those phosphorylated in NKCC1 [51] . Activation of PKC (protein kinase C) by phorbol esters inhibits transport [59] . Much more is known about how various factors influence the surface expression of the protein, as this is relevant to understanding the pathology of Gitelman's disease [61, 62] . The transporter has been functionally expressed in Xenopus oocytes allowing precise measurement of thiazide-sensitive Na + fluxes [58, 62] . The expressed NCC, like other CCCs, forms homodimers which may be important in its function [63] . In order to be properly trafficked to the cell surface, the transporter must be correctly folded and glycosylated [62, 64] . Although significant amounts of NCC get inserted into the oocyte surface membrane, large amounts also accumulate internally as an immaturely glycosylated form that is not seen in native DCT membranes [61] , perhaps indicating that caution should be exercised when interpreting aspects of these data. Initial attempts to express NCC in mammalian cells to allow assessment of its properties in a more appropriate environment were not wholly successful, although functional expression was achieved in MDCK cells [64] . Although the level of expression was low, glycosylation pattern of the expressed protein was similar to that in native DCT cells [61] . More recently, success has been achieved with expressing the transporter in COS-7 and M1 cells [65] .
Gitelman's disease
This is a rare autosomal-recessive condition characterized by hypotension with hypokalaemia and metabolic alkalosis, together with hypocalciuria and hypomagnesaemia. Initially described as a variant of Bartter's disease, it quickly became recognized as a separate disease arising from a different set of Na + -transporting deficiencies. Although hypomagnesaemia may be observed in some types of Bartter's disease, severe hypomagnesaemia is one of the defining feature of Gitelman's disease. The condition is reminiscent of intoxication with thiazide diuretics, pointing to its origins from deficits in the Na + -reabsorbing module in the DCT [1,2,56] (Figure 2 ). Gitelman's disease can be traced to a variety of loss-offunction mutations in NCC (at least 80 mutations in SLC12A3), many of which reduce the efficiency with which the transporter is inserted into the apical membrane [61, 62] . As pointed out above, NCC probably exists in the membrane as a dimer. Expression studies suggest that mutant copies of the protein can form dimers with wildtype channels, in some cases preventing trafficking of the latter to the membrane [63] . In these cases, defective molecules not only lack transport capacity, but also prevent wild-type transporters from functioning properly.
The extracellular volume contraction that occurs in Gitelman's disease not only stimulates aldosterone secretion, but also causes an increase in paracellular Ca 2+ reabsorption in the proximal tubule, which is facilitated by increased proximal Na + reabsorption [60] . This produces the hypocalciuria observed. Chronic thiazide administration or knockout of the SLC12A3 gene have both been observed to reduce the expression of the TRPM6 (transient receptor potential melastatin 6) channel in the DCT [60] . This channel is a major route for Mg 2+ reabsorption in the DCT, so it is possible that the loss-of-function mutations in the NaCl cotransporter in Gitelman's disease somehow reduce the expression of TRPM6 and lead to Mg 2+ wasting. Unlike Bartter's disease, defects in other elements of the Na + -reabsorbing module in the DCT have not been reported for Gitelman's disease. From a molecular point of view, problems with DCT Na + reabsorption would be expected with mutations in CLCNKB and BSND (Barttin) as the proteins are involved in Cl − exit from DCT as well as TAL cells. It is therefore possible that types III and IV of Bartter's disease either have DCT involvement or there is another major route for Cl − exit in DCT cells.
Gordon's disease
Gordon's disease, also known as PHAII (pseudohypoaldosteronism type II), is an autosomal-dominant form of salt-sensitive hypertension, accompanied by hyperkalaemia and renal tubular acidosis despite normal glomerular filtration and normal or raised aldosterone levels [7, 66] . The condition is exquisitely sensitive to treatment with thiazide diuretics, suggesting a primary defect in salt reabsorption in the DCT (the condition appears to be the inverse of Gitelman's disease). However, genome-wide analysis found no linkage with NCC, but instead with genes on chromosomes 1, 12 and 17 [7] , and perhaps others too [67] . The gene on chromosome 1 has not been identified, but the genes on chromosomes 12 and 17 were identified as WNK1 and WNK4 respectively (Table 1) . These targets were completely unexpected. They code for recently described serine/threonine kinases that are unusual in that a lysine residue, which is normally found in the catalytic site of kinases, is replaced by a cysteine residue [hence the name with-no-lysine (K) kinase] [5, 67, 68] . The mutations that cause Gordon's disease produce a gain-of-function for WNK1 (levels of WNK1 in white cells of affected individuals are raised) or loss-of-function of WNK4. How do these stimulate Na + retention and suppress K + secretion in the distal tubule?
WNK1, WNK4 and surface expression of NCC
Both WNK1 and WNK4 are found in the cytoplasm of distal tubule cells, and WNK4 is also strongly associated with the tight junction complexes, a position where it might influence ion flux by the paracellular route [7] . Coexpression of WNK4 with NCC in Xenopus oocytes reduced Na + transport and this was associated with reduced surface expression of NCC despite normal cell synthesis [69] . Some, but not all, WNK4 mutations found in Gordon's disease allow surface expression of NCC, suggesting that loss-of-function mutations of WNK4 may result in increased surface expression of NCC and perhaps excessive reabsorption of Na + in the DCT [69, 70] . In addition, kinase-dead mutations (manufactured in the laboratory) prevent the inhibitory effect of WNK4 on NCC surface expression [70] , suggesting a role for phosphorylation in this process. Exactly what needs to be phosphorylated to reduce NCC surface expression has not been established. The situation is complicated further by the observation that the C-terminal 222 amino acids of WNK4 are sufficient to suppress NCC activity and yet this form lacks the kinase domain [71] . It seems likely that the C-terminus of WNK4 interacts with the C-terminus of NCC, and the N-terminus interacts with the kinase domain of WNK1 and perhaps other regulatory molecules [71] . These effects of WNK4 on NCC expressed in Xenopus oocytes have been confirmed in mammalian expression systems (COS-7 and M-1), where it was possible to show that reduced surface expression of NCC is not due to increased clathrindependent retrieval, but possibly to increased degradation of NCC by lysosomes (inhibited by bafilomycin A1) [65] .
Co-expression of WNK1 with NCC had no effect on surface expression of the cotransporter, but co-expression of WNK1 with NCC and WNK4 relieved the inhibition that WNK4 normally produced on cotransporter surface expression [69] . Thus the gain-of-function mutations in WNK1 seen in Gordon's disease should result in increased expression of NCC in the DCT. Kinase-dead or truncated forms of WNK1 do not affect inhibition of NCC surface expression by WNK4 [72] . Although WNK1 is probably ubiquitously expressed, a truncated version, lacking the kinase domain [KS-WNK1 (kidney-specific WNK1)], is exclusively expressed in the distal nephron [73] . Coexpression studies with NCC in Xenopus oocytes show that KS-WNK1 binds to (full-length) WNK1 to inhibit its effects on WNK4. The resulting disinhibition of WNK4 allows it to reduce NCC surface expression. Thus we see the emergence of a kinase cascade to regulate the behaviour of target molecules, permitting fine physiological control over outcomes [74] . The discovery of this truncated and predominant form of WNK1 in the distal nephron requires the re-examination of the effects of WNK1 mutations in Gordon's disease. High levels of WNK1 in white cells were reported [7] . It now appears that in order to understand the kidney's role, we need to know how the mutations affect the balance of WNK1 and KS-WNK1 in the distal tubule itself.
Although WNK4 mutations caused increased NCC expression in the DCT, they reduce the surface expression of ROMK channels in CD cells [66, 75] , probably by increasing the rate at which these channels are removed from the surface by clathrin-mediated endocytosis [75] . Kinase-dead WNK4 mutations were particularly potent at stimulating endocytosis of ROMK channels [67, 75] .
As stated above, WNK4 is found associated with tight junction complexes where it may regulate the phosphorylation and permeability of claudins in these junctions [76] . WNK4 mutations that increase surface expression of NCC and reduce expression of ROMK channels also increase the phosphorylation of claudins, increasing Cl − permeability through the paracellular pathway. Thus the pathology in Gordon's disease results from overactivity of NCC in the DCT, leading to Na + retention and hypertension that is sensitive to thiazides, and reduced surface expression of ROMK channels and increased paracellular Cl − permeability in the distal tubule, reducing K + secretion.
WNKs AND THE REGULATION OF TRANSPORTERS
Although it was initially thought that WNK1 and WNK4 are selectively expressed in the distal tubule of the kidney, it is now clear that they are found in many salt-transporting epithelia [6, 77, 78] . WNK1 has kinase activity when expressed, whereas WNK4 does not display kinase activity unless activated by as yet unknown factors [79] . Relatively few WNK substrates have been identified (or indeed are expected to exist [54] ) and these include SPAK, OSR1 [4, 54] , claudins 1-4 [76] , synaptotagmin 2 [80] and other WNKs [6] . WNKs interact with each other, and WNK1 can phosphorylate WNK2 and WNK4 [6] .
It has yet to be reported whether WNK1 or WNK4 can directly phosphorylate any of the regulatory serine or threonine residues on CCCs. In co-expression studies WNK4 was shown to reduce the surface expression of NKCC1, the anion-exchanger CFEX (Cl − -formate exchanger) [78] and TRPV4 (transient receptor potential channel V4) [81] , a non-selective cation channel that plays important roles in osmosensing. Full-length WNK1 has recently been shown to inhibit ROMK channel expression in oocytes and HEK cells independently of WNK4 [72, 82, 83] . KS-WNK1 inhibits the effect of fulllength WNK1 on ROMK channel expression [72, 82] .
Although the results of studies in which WNK1 was overexpressed make physiological sense, interpreting the results of studies on WNK4 are more challenging. One problem is to reconcile the inhibition of NKCC1 surface expression by WNK4 with its stimulation of NKCC1 phosphorylation and transport activity (through SPAK/OSR1). Perhaps the problems arise because WNK4 is an inactive kinase when expressed. Clearly there is still much to learn about how these molecules behave under more physiological conditions.
WNK3
Analysis of Gordon's disease indicated the involvement of WNK1 and WNK4 in the regulation of transporters, in particular the CCCs. There are four WNK genes in humans [68] , so the question arises whether WNK2 and WNK3 are also involved in these processes. Currently, there is no information on WNK2 in this respect, but recent work indicates that WNK3 plays a pivotal role in regulating CCC function. WNK3 is an active protein kinase when immunoprecipitated from HEK cells [84] and is thought to promote cell survival. Interestingly, WNK3 is found on the X chromosome, suggesting that gender may have an impact on these processes. The protein is widely expressed, but especially in brain and kidney (Table 1) . Particularly high levels are found at intercellular junctions [85] .
WNK3 increases the surface expression of NCC and NKCC2 in Xenopus oocytes [85] , increases the phosphorylation and activation of NKCC2 [85] and NKCC1 [86] , and increases the phosphorylation and thus inhibits KCC1-KCC4 [87] . It inhibits the surface expression of ROMK channels, but not that of ENAC [88] , and it has no effect on claudins [88] . WNK3 thus activates transporters that bring Cl − into cells (NKCC1, NKCC2 and NCC), but inhibits those that remove it (KCC1-KCC 4). Cytoplasmic [Cl − ] is an important determinant of epithelial function and helps co-ordinate fluxes across the apical and basolateral membranes, possibly by affecting phosphorylation of the transporters [34, 89] . Thus WNK3 (and perhaps other WNKs too) may be part of the feedback loop that fine-tunes transporter activity; however, we still need to discover if and how cell [Cl − ] affects WNK activity. An interesting point to emerge from this work was the finding that WNK3 might phosphorylate and inhibit PrP1 [87] , an enzyme that has a critical role in regulating CCC function. It was also suggested that WNK3 may serve as a scaffold helping to bring together PrP1 and KCC. This was based on the observation that kinase-dead WNK3 activates (facilitates dephosphorylation of) KCC under isotonic conditions [87] . An alternative explanation is that the overexpression of kinase-dead WNK3 causes so much competition that any active WNK3 in the cell has little chance of phosphorylating PrP1.
WNKs, CCCs and BP
Essential hypertension, a scourge of modern living, is on the increase, leading to increased morbidity and mortality. This may be partly due to increased salt consumption by a population put as risk by genes that once aided survival by facilitating salt and water conservation when these were scarce [9, [90] [91] [92] . To date, all of the genes identified with a clear link to essential hypertension are involved in salt transport in the kidney [9] . This makes physiological sense as, without kidney involvement, pressure natriuresis should prevent the development of hypertension [8, 91] . With a better understanding of the molecular defects that predispose an individual to developing this condition [93, 94] , it should be possible to target therapy more appropriately and effectively.
We have seen that mutations to WNK1 and WNK4 cause the hypertension associated with Gordon's disease. This has sparked an interest in the role of WNKs in the regulation of BP more generally. Recent studies have shown that variations in WNK1 may contribute to the variations in BP seen in the general population [95] [96] [97] . Heterozygous WNK1-deficient mice have been generated (mice homozygous for the WNK1 mutation die before birth), and these have a mean BP approx. 12 mmHg less than wild-type animals [98] . Again, this supports a role for WNKs in BP regulation possibly through effects on CCC transporters in the kidney, although it should not be forgotten that NKCC1, and probably KCCs, play a role in regulating vascular muscle tone [99, 100] . The role of NKCC1 is underscored by the observation that loop diuretics, which are potent inhibitors of this transporter, appear to have a direct BP-reducing effect on the vasculature, and that NKCC1 (SLC12A2)-deficient mice have lower BP than wild-type mice [101] .
For many years, investigators have pursued a connection between hypertension and defects in NKCC1 following initial observations that Na + -K + -2Cl − cotransport activity in red blood cells of hypertensives was higher than in normotensive controls [94, 100] . It was felt that a simple measurement on red blood cells from individuals in at-risk groups might inform clinicians about appropriate therapeutic strategies or lifestyle advice. However, larger studies failed to find a clear correlation [102] , suggesting that measurements of red blood cell Na + -K + -2Cl − cotransport rate had no diagnostic value in essential hypertension. We are now in a position to understand why a connection between hypertension and red blood cell NKCC activity might exist. Rather than being due simply to a defect in NKCC1 itself, these differences in transport rate might better reflect defects in transport regulation by molecules such as the WNKs which also regulate Na + transport by CCCs in the kidney and vasculature. Thus red blood cells might still prove a useful biopsy material as long as we can find simple robust techniques to assess how their CCCs are regulated.
So far this analysis has concentrated on how mutations in genes that regulate salt transport in the TAL or DCT may give rise to hypertension. I would now like to explore whether mutations to the transporters themselves can cause hypertension. To date, no gain-of-function mutations in NKCC2 (SLC12A1) or NCC (SLC12A3) have been reported; however, a polymorphism has been found in the gene for the Cl − exit channel CLCKB (CLCNKB) that is necessary for Na + reabsorption in both the TAL and DCT [103] . Between 20-40 % of the populations studied were heterozygous for a gain-offunction mutation in CLCNKB which caused a 7-fold increase in Cl − current when the channels were expressed in Xenopus oocytes. Carriers of the mutations had higher BP and plasma [Na + ], and a much higher prevalence of hypertension. This very interesting preliminary finding also implies that Na + reabsorption in the TAL and DCT is normally limited by the rate of basolateral Cl − exit. However, further work needs to be done with larger populations to rule out population stratification as a possible alternative explanation of the data [104] .
I would now like to consider whether recent molecular studies shine any light on the controversy concerning the role of altered Mg 2+ homoeostasis in the genesis of essential hypertension [105, 106] . Whereas it seems reasonably clear that hypomagnesaemia could exacerbate hypertension by increasing vascular reactivity (less competition for Ca 2+ entering cells) and perhaps by stimulating Na + reabsorption by NKCC2 in the TAL due to reduced activation of CASR (Figure 1) , it is less clear whether significant changes in intracellular [Mg 2+ ] occur during the genesis of hypertension and, if they do occur, whether these have an impact on the mechanisms causing the hypertension. Recently, it has been found that the level of TRPM7, a channel that allows Mg 2+ to enter cells, is significantly reduced in vascular smooth muscle from hypertensive rats [107, 108] . This channel is closely related to TRPM6 (see above), a channel whose expression is reduced both in Gitelman's disease as a result of reduced NCC expression and by chronic inhibition of NCC with thiazides [60] . Thus there is the intriguing possibility that TRPM6 and TRPM7 interact with CCCs in such a way that defects in CCCs, or the way in which they are regulated, may directly alter the ability of Mg 2+ and Ca 2+ to enter cells.
Aldosterone, WNKs and the independent control of Na + and K + transport
Raised plasma aldosterone levels cause the kidney to increase both Na + reabsorption and K + secretion. However, there are many situations where it is necessary to control Na + reabsorption and K + secretion independently of each other. How is this achieved? This intransigent physiological problem may at last be close to solution. WNK4 and possibly WNK3 may act as molecular switches so that when aldosterone secretion is due to hypovolaemia then Na + reabsorption is stimulated without excessive K + loss, whereas when aldosterone is released due to high plasma [K + ], then K + loss is stimulated without Na + retention [66, 75, 109] . The concept is that, under normal conditions when aldosterone levels are low, WNK4 prevents routing of NCC to the apical membrane of the DCT (low Na + reabsorption) and increases the removal of the ROMK channel from the principal cells of the CD (low K + secretion). Raised aldosterone due to hypovolaemia relieves inhibition of NCC routing by WNK, resulting in extra Na + reabsorption, whereas when aldosterone is raised due to hyperkalaemia the scavenging of the ROMK channel is stopped and additional K + is secreted. This differential effect of WNK4 could be brought about by changes in its activation state or interaction with other WNKs.
THERAPEUTIC IMPLICATIONS
The realization that defects in NaCl reabsorption (and its regulation) in the TAL or DCT can cause hypertension implies that diuretics are not simply part of the therapeutic armamentum for this condition, but may be the most appropriate treatment since they target the root cause. As it becomes increasingly possible to identify molecular defects in NaCl-reabsorbing modules within patients, it should be possible to determine whether thiazides, or indeed loop diuretics, are the most appropriate treatment. Currently, these compounds are rather blunt instruments that directly inhibit the transporters, but it should be possible to develop new diuretics that affect the regulatory mechanisms instead. Such compounds could offer more flexible control over Na + reabsorption, allowing Na + reabsorption under some circumstances while restricting it under others. Some current side-effects could be eliminated if the compounds were targeted more precisely at appropriate tissues. If defects in NKCC1 make a significant contribution to essential hypertension, targeting therapy may be more challenging because of the universal distribution of this transporter, although control over transport in certain key cell types may be possible if, as we believe, some aspects of NKCC1 regulation are tissue-specific. Finally, our increasing awareness of possible links between CCCs, Mg 2+ transporters and hypertension highlight the need for proper assessment of, and attention to, Mg 2+ status of patients, especially those receiving long-term diuretic therapy.
CONCLUSIONS
We are witnessing a very exciting time in transport physiology with the emergence of new data and paradigms to explain several problems that have resisted scrutiny in the past. We can begin to explain some varieties of essential hypertension and understand how aldosterone independently regulates Na + and K + transport, and we have identified some of the kinases that regulate CCC function (Figure 3) . However, I want to end on a slightly cautionary note. Much of the work I have described relies on the overexpression of proteins. Using a cell as a factory to make rare molecules has permitted huge advances in our knowledge and understanding of physiology and medicine. It is particularly useful in exploring the properties of transporters, enzymes and receptors; however, we are also aware that it is possible to bring together partners that would not normally meet in their native environment, for instance molecules restricted to apical or basolateral membranes. We also know that the choice of expression system can have an enormous impact on outcome. The Xenopus oocyte is a wonderful system if the final function to be assayed is ion transport. However, it is not a mammalian cell and may process some proteins differently, as has become evident in the studies of cystic fibrosis or indeed NCC. Temperature can have a big impact on protein folding and signalling pathways may need extra features to run successfully at 37
• C, but I think we need to exercise particular care when using the technique to explore cell signalling cascades. The overexpression of a molecule that Blocks in green indicate activated proteins, whereas those in red are inactive. Active WNK1 and WNK4 phosphorylate SPAK/OSRI which can now phosphorylate CCCs, perhaps permitting further phosphorylation by other kinases. CCC phosphorylation activates NKCC1 and NKCC2, but inhibits the KCCs. The effect of NCC phosphorylation is not known. CCCs are dephosphorylated by PrP1, a phosphatase that is inhibited by phosphorylation by WNK3. Thus WNK3 maintains CCCs in a phosphorylated state.
is part of a complex web of feedback and feedforward may generate data that are difficult to interpret, and may appear counterintuitive without the explanatory power of suitable mathematical models. We enthusiastically await results from studies using a wider variety of systems and more physiological expression levels and the development of those all-important models.
